Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.31 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18805347 | 0.81 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL11701735 | 0.77 | SMN1; SMN2 (0.49) | ALDH1A1ENPP2LPAR2SMN1; SMN2 | |
| SCHEMBL18818891 | 0.76 | — | — | |
| SCHEMBL20022659 | 0.75 | — | — | |
| SCHEMBL11699083 | 0.74 | PPARD (0.45) | ALDH1A1ENPP2LPAR2SMN1; SMN2 | |
| SCHEMBL776263 | 0.73 | LAP3 (0.36) | ALDH1A1 | |
| SCHEMBL7419651 | 0.72 | ANPEP (0.38) | — | |
| SCHEMBL14777095 | 0.71 | — | — | |
| SCHEMBL1251447 | 0.71 | PPARD (0.35) | — | |
| SCHEMBL11745106 | 0.71 | LAP3 (0.34) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118146260-A | Unsaturated cationic phosphonate modified bis-salicylaldehyde primary diamine and preparation method thereof | 长治学院 | 2024-06-07 | — | — | CN | disclosed |
| CN-118063505-A | Unsaturated gemini Ji An acid ester and preparation method thereof | 江苏海洋大学 | 2024-05-24 | — | — | CN | disclosed |
| US-7414071-B2 | Methods of treatment with selective EP4 receptor agonists | PFIZER INC. (US) | 2008-08-19 | — | — | US | disclosed |
| EP-1339678-B1 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | PFIZER PROD INC (US) | 2007-09-26 | — | — | EP | disclosed |
| US-7192979-B2 | EP4 receptor selective agonist in the treatment of osteoporosis | PFIZER INC. (US) | 2007-03-20 | — | — | US | disclosed |
| EP-1487437-B1 | USE OF SELECTIVE EP4 RECEPTOR AGONISTS FOR THE TREATMENT OF DISEASES | PFIZER PROD INC (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20040259921-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PFIZER INC | 2004-12-23 | — | — | US | disclosed |
| EP-1487437-A1 | METHODS OF TREATMENT WITH SELECTIVE EP4 RECEPTOR AGONISTS | Pfizer Products Inc. (US) | 2004-12-22 | — | — | EP | disclosed |
| US-6747054-B2 | FOR THERAPY OF LOW BONE MASS, PARTICULARLY OSTEOPOROSIS, FRAILTY, AN OSTEOPOROTIC FRACTURE, A BONE DEFECT, CHILDHOOD IDIOPATHIC BONE LOSS, ALVEOLAR BONE LOSS, MANDIBULAR BONE LOSS, BONE FRACTURE, OSTEOTOMY | PFIZER INC. | 2004-06-08 | — | — | US | disclosed |
| US-20030207925-A1 | Methods of treatment with selective EP4 receptor agonists | CAMERON KIMBERLY O (US) | 2003-11-06 | — | — | US | disclosed |
| EP-1339678-A2 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | Pfizer Products Inc. (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20030149086-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | CAMERON KIMBERLY O (US) | 2003-08-07 | — | — | US | disclosed |
| US-6552067-B2 | For therapy of osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, bone loss associated with periodontitis | PFIZER INC. | 2003-04-22 | — | — | US | disclosed |
| US-20020065308-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | LOTUS PHARMACEUTICAL CO., LTD. (JP) | 2002-05-30 | — | — | US | disclosed |
| WO-2002042268-A2 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | PFIZER PRODUCTS INC. (US) | 2002-05-30 | — | — | WO | disclosed |
| US-4211850-A | Polyhydroxy compounds containing urethane aryl sulfonic acid hydroxyalkyl ester groups | BAYER AKTIENGESELLSCHAFT (DE) | 1980-07-08 | — | — | US | disclosed |
| US-4201852-A | Polyurethanes based on modified polyisocyanates containing sulphonic acid ester groups and process for the production thereof | BAYER AKTIENGESELLSCHAFT (DE) | 1980-05-06 | — | — | US | disclosed |
| US-4189562-A | Polyhydroxy compounds containing urethane aryl sulfonic acid hydroxyalkyl ester groups | BAYER AKTIENGESELLSCHAFT (DE) | 1980-02-19 | — | — | US | disclosed |
| US-4048374-A | Functional organophosphonic acid esters as preservative adhesion promoting agents and coating for metals | DYNAMIT NOBEL AKTIENGESELLSCHAFT (DT) | 1977-09-13 | — | — | US | disclosed |
| US-4029679-A | PROTECTIVE METAL COATING | DYNAMIT NOBEL AKTIENGESELLSCHAFT (DT) | 1977-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207925-A1 | Methods of treatment with selective EP4 receptor agonists | PTGER4, PTGER1, PTGER2 | ALDH1A1 1330/4885ENPP2 47/4885LPAR2 101/4885 |
| US-20040259921-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | ALDH1A1 2220/4885ENPP2 153/4885LPAR2 243/4885 |
| US-20030149086-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | ALDH1A1 2541/4885ENPP2 139/4885LPAR2 189/4885 |
| US-20020065308-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | ALDH1A1 2541/4885ENPP2 139/4885LPAR2 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.